NIH: Prodromal α-Synucleinopathies Consortium (PαSS) (U19 Clinical Trial Optional)

This FOA seeks to develop and support a consortium of investigators who will establish a common idiopathic REM sleep behavior disorder (iRBD) research protocol to collect and share harmonized clinical, cognitive, and biomarker data, establishing a centralized repository of biosamples from individuals with iRBD as they progress from prodromal α-synucleinopathy to Parkinson’s disease, Lewy Body Dementia, or Multi-System Atrophy.

Deadline: June 17, 2020

More information.